Samsung invests $110M in healthcare firm GRAIL to expand cancer test into Korea, Asia
The United States-based healthcare firm GRAIL has closed an equity financing deal in which Samsung affiliates, including Samsung C&T Corporation, invested $110 million through the purchase of GRAIL common stock at $70.05 per share.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed